Gross Motor Function in Pediatric Onset <i>TUBB4A</i> -Related Leukodystrophy: GMFM-88 Performance and Validation of GMFC-MLD in <i>TUBB4A</i>
Francesco Gavazzi(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), Geneviève Bernard(McGill University), Tracy Kornafel(Children's Hospital of Philadelphia), Allan M. Glanzman(Boston Children's Hospital), Nicole I. Wolf(Emma Kinderziekenhuis), Anjana Sevagamoorthy(Children's Hospital of Philadelphia), Davide Tonduti, Sarah Woidill(Children's Hospital of Philadelphia), Brittany A. Charsar(Children's Hospital of Philadelphia), Virali Patel(Children's Hospital of Philadelphia), Jacqueline Erler(Children's Hospital of Philadelphia), Emma McKenzie(Amsterdam UMC Location Vrije Universiteit Amsterdam), Marjo S. van der Knaap(Amsterdam Neuroscience), Brielle Formanowski(Children's Hospital of Philadelphia), Samuel R. Pierce(Children's Hospital of Philadelphia), Evangeline Wassmer(Birmingham Children's Hospital), Elizabeth Ballance(Children's Hospital of Philadelphia), Francesca Magrinelli(National Hospital for Neurology and Neurosurgery), Justine Shults(Children's Hospital of Philadelphia), Michelle Teng, Laura Adang(Children's Hospital of Philadelphia)
Cited by 11
Related Papers
Characterization of human disease phenotypes associated with mutations in <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADAR</i>, and <i>IFIH1</i>
|American Journal of Medical Genetics Part A|2015|617
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441
Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation
|Parkinson s Disease|2016|374